Abstract
Type 2 diabetes mellitus (T2DM) is characterized by a progressive failure of pancreatic β-cell function (BCF) with insulin resistance. Once insulin over-secretion can no longer compensate for the degree of insulin resistance, hyperglycemia becomes clinically significant and deterioration of residual β-cell reserve accelerates. This pathophysiology has important therapeutic implications. Ideally, therapy should address the underlying pathology and should be started early along the spectrum of decreasing glucose tolerance in order to prevent or slow β-cell failure and reverse insulin resistance. The development of an optimal treatment strategy for each patient requires accurate diagnostic tools for evaluating the underlying state of glucose tolerance. This review focuses on the most widely used methods for measuring BCF within the context of insulin resistance and includes examples of their use in prediabetes and T2DM, with an emphasis on the most recent therapeutic options (dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists). Methods of BCF measurement include the homeostasis model assessment (HOMA); oral glucose tolerance tests, intravenous glucose tolerance tests (IVGTT), and meal tolerance tests; and the hyperglycemic clamp procedure. To provide a meaningful evaluation of BCF, it is necessary to interpret all observations within the context of insulin resistance. Therefore, this review also discusses methods utilized to quantitate insulin-dependent glucose metabolism, such as the IVGTT and the euglycemic-hyperinsulinemic clamp procedures. In addition, an example is presented of a mathematical modeling approach that can use data from BCF measurements to develop a better understanding of BCF behavior and the overall status of glucose tolerance.
Keywords: β-cell function, DPP-4 inhibitor, euglycemic-hyperinsulinemic clamp, GLP-1 receptor agonist, glucose tolerance test, hyperglycemic clamp, meal tolerance test.
Current Diabetes Reviews
Title:Assessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications
Volume: 10 Issue: 1
Author(s): Eugenio Cersosimo, Carolina Solis-Herrera, Michael E. Trautmann, Jaret Malloy and Curtis L. Triplitt
Affiliation:
Keywords: β-cell function, DPP-4 inhibitor, euglycemic-hyperinsulinemic clamp, GLP-1 receptor agonist, glucose tolerance test, hyperglycemic clamp, meal tolerance test.
Abstract: Type 2 diabetes mellitus (T2DM) is characterized by a progressive failure of pancreatic β-cell function (BCF) with insulin resistance. Once insulin over-secretion can no longer compensate for the degree of insulin resistance, hyperglycemia becomes clinically significant and deterioration of residual β-cell reserve accelerates. This pathophysiology has important therapeutic implications. Ideally, therapy should address the underlying pathology and should be started early along the spectrum of decreasing glucose tolerance in order to prevent or slow β-cell failure and reverse insulin resistance. The development of an optimal treatment strategy for each patient requires accurate diagnostic tools for evaluating the underlying state of glucose tolerance. This review focuses on the most widely used methods for measuring BCF within the context of insulin resistance and includes examples of their use in prediabetes and T2DM, with an emphasis on the most recent therapeutic options (dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists). Methods of BCF measurement include the homeostasis model assessment (HOMA); oral glucose tolerance tests, intravenous glucose tolerance tests (IVGTT), and meal tolerance tests; and the hyperglycemic clamp procedure. To provide a meaningful evaluation of BCF, it is necessary to interpret all observations within the context of insulin resistance. Therefore, this review also discusses methods utilized to quantitate insulin-dependent glucose metabolism, such as the IVGTT and the euglycemic-hyperinsulinemic clamp procedures. In addition, an example is presented of a mathematical modeling approach that can use data from BCF measurements to develop a better understanding of BCF behavior and the overall status of glucose tolerance.
Export Options
About this article
Cite this article as:
Cersosimo Eugenio, Solis-Herrera Carolina, Trautmann E. Michael, Malloy Jaret and Triplitt L. Curtis, Assessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications, Current Diabetes Reviews 2014; 10 (1) . https://dx.doi.org/10.2174/1573399810666140214093600
DOI https://dx.doi.org/10.2174/1573399810666140214093600 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Contemporary Risk Assessment and Cardiovascular Outcomes in Peripheral Arterial Disease
Cardiovascular & Hematological Disorders-Drug Targets Mitochondrial Triglyceride Transfer Protein Inhibition: New Achievements in the Treatment of Dyslipidemias
Current Pharmaceutical Design Cell-Penetrating Peptides as a Potential Drug Delivery System for Effective Treatment of Diabetes
Current Pharmaceutical Design Sirtuins as Possible Drug Targets in Type 2 Diabetes
Current Drug Targets Development of Controlled Release Osmotic Pump Tablet of Glipizide Solid Dispersion
Current Drug Delivery Hepatobiliary Diseases and Insulin Resistance
Current Medicinal Chemistry Role of CYP2E1 in Mitochondrial Dysfunction and Hepatic Injury by Alcohol and Non-Alcoholic Substances
Current Molecular Pharmacology Intravenous Glycoprotein IIb / IIIa Antagonists: Their Benefits, Problems and Future Developments
Current Pharmaceutical Design Modeling and Informatics in Designing Anti-Diabetic Agents
Current Pharmaceutical Design Quantum Dots as Promising Theranostic Tools Against Amyloidosis: A Review
Protein & Peptide Letters Literature Review on Diabetes Internet-based Spanish-Language Information
Current Diabetes Reviews Regulatory Mechanisms of Calcineurin Phosphatase Activity
Current Medicinal Chemistry What’s Age Got to do with it? A Review of Contemporary Revascularization in the Elderly
Current Cardiology Reviews Nutritional and therapeutic approaches to modulate NADPH oxidase-derived ROS signaling in platelets.
Current Pharmaceutical Design Effects of Antidiabetic Drugs on Muscle Mass in Type 2 Diabetes Mellitus
Current Diabetes Reviews Thyroid Hormones Crosstalk with Growth Factors: Old Facts and New Hypotheses
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Nmr Studies Of The Prionogenic Peptide Derived From Sup35 Protein
Protein & Peptide Letters Hutchinson-Gilford Progeria Syndrome (Hgps) and Application of Gene Therapy Based Crispr/Cas Technology as A Promising Innovative Treatment Approach
Recent Patents on Biotechnology Intracellular Fatty Acid Metabolism in Skeletal Muscle and Insulin Resistance
Current Diabetes Reviews Genetic Analysis of Aldose Reductase in Diabetic Complications
Current Medicinal Chemistry